Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMMNC in Multiple Sclerosis
NCT01883661Phase 2Unknown
- Sponsor
- Chaitanya Hospital
- Start
- Jun 2014
- Primary completion
- Nov 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in multiple sclerosis (MS), sponsored by Chaitanya Hospital. Primary endpoint: Analysis of patients symptoms at 6 months. Status: unknown.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01883661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01883661.